IMD 0354,
IMD-0354,
IMD0354,
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide,
IMD-0354,
978-62-1,
IMD 0354,
IKK-2 Inhibitor V,
IMD0354,
TCMDC-125465,
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide,
UNII-76145IS906,
N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide,
CHEMBL536151,
N-(3,5-Bis-trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide,
MFCD00218820,
76145IS906,
Benzamide, N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxy-,
Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxy-,
CHILCFMQWMQVAL-UHFFFAOYSA-N,
IKK2 Inhibitor V,
Kinome_1864,
AC1NO40S,
C15H8ClF6NO2,
MLS006011200,
SCHEMBL129165,
CHEBI:93310,
CTK8G0277,
AOB5931,
DTXSID50243248,
HMS3229F11,
HMS3269F13,
HMS3651D21,
HMS3677J21,
BCP22358,
KS-00000T7G,
ZINC3986227,
2473AH,
BDBM50430160,
IN1463,
s2864,
AKOS017344958,
BCP9000777,
CS-4922,
SB19541,
3',5'-Salicyloxylidide, 5-chloro-alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro-,
NCGC00165811-01,
NCGC00165811-02,
NCGC00165811-03,
NCGC00165811-06,
AK176084,
BC600653,
HY-10172,
SMR004702969,
BCP0726000026,
IMD-0354, >=98% (HPLC), solid,
SW219746-1,
BRD-K74305673-001-01-3,
5-Chloro-2-hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide,
5-chloro-2-hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-benzamide,
N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxy-benzamide,
D0Z5DM,
IMD-2560,
IMD-2560),
CID5081913,
B1587,
A12837,
C492919,
IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD,
IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD,
IMD-0354, 99%, a synthetic selective NF-kB inhibitor - 100MG 100mg,
I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD,
I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign,